Heads up! FDA Panel Gives Nod to Bird Flu Vaccine 16 Nov 2012 An FDA advisory panel has voted in favor of a vaccine against with the highly pathogenic H5N1 avian flu that would be stockpiled and used in case of [the next US-engendered] pandemic. By twin votes of 14-0, the panel agreed that the immunogenicity and the safety of the vaccine, made in Quebec by GlaxoSmithKline, were enough to meet licensing standards under accelerated approval regulations. Those rules, set in 2007, allow rapid approval of a vaccine on the basis of markers that are likely to predict clinical benefit. The Q-Pan H5N1 vaccine, developed under contract with the Department of Health and Human Services, consists of a monovalent, inactivated, split A/H5N1 influenza virus antigen and Glaxo's AS03 adjuvant.